Are you considering adding exposure to the China healthcare sector to your investment portfolio? Now might be an opportune moment to do so. Earlier this month, the <\/span>South China Morning Post<\/span><\/a> reported that China’s healthcare sector has raised approximately $10.6 billion in fundraising this year, according to Dealogic. Notably, the fundraising figures for 2025 have already surpassed the combined totals from 2022, 2023, and 2024.<\/span><\/p>\n The article spotlighted several key players in the China healthcare landscape who are at the forefront of this fundraising surge. For instance, Wuxi AppTec successfully raised around $980 million through a share placement in Hong Kong. Additionally, Hansoh Pharmaceutical Group recently secured $500 million via a new shares issue, showcasing the robust activity in this sector.<\/span><\/p>\n Fundraising has also been bolstered through initial public offerings (IPOs). Jiangsu Pharmaceuticals, for example, raised about $1.3 billion through its Hong Kong listing <\/span>earlier this year<\/span><\/a>.<\/span><\/p>\n With record amounts of capital flowing into the healthcare sector, both advisors and investors should consider increasing their exposure to these leading Chinese healthcare companies. These firms not only provide essential diversification but are also well-positioned to deliver significant long-term growth.<\/span><\/p>\n For those interested in expanding their portfolio with China healthcare companies, KraneShares offers a compelling solution. The <\/span>KraneShares MSCI All China Health Care Index ETF (KURE)<\/span><\/a> is designed for situations like this.<\/span><\/p>\n KURE provides efficient and direct access to many of China’s leading healthcare firms within a cost-effective ETF structure. Notably, WuXi AppTec, Hansoh Pharmaceutical Group, and Jiangsu Pharmaceuticals are among the top holdings in the fund’s portfolio.<\/span><\/p>\n This strategic positioning allows KURE to capitalize on the momentum in China\u2019s healthcare fundraising. With several of the fund’s top holdings achieving impressive fundraising results, KURE is well-positioned to deliver attractive returns in both the short and long term.<\/span><\/p>\n So far this year, KURE has demonstrated remarkable performance, despite facing challenges such as tariffs. As of August 31, 2025, the fund’s net asset value (NAV) has increased by 41.47% year-to-date.<\/span><\/p>\nKURE Offers Exposure to China\u2019s Healthcare Giants<\/h2>\n
![\"\"\/](\"https:\/\/www.etftrends.com\/wp-content\/themes\/smart-mag\/images\/newsletter-embeds\/newsletter-first.jpg\")
\n <\/div>\n